Drug Trial Radar · NCT04026997
A Phase 2 Study of CIN-102 in Adults With Idiopathic and Diabetic Gastroparesis
Last checked: Nov 19, 2026Latest source record: Mar 25, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Terminated
Enrollment
72
Actual
Start
Sep 11, 2019
Primary completion
Dec 17, 2020
Study completion Dec 17, 2020
Sponsor
- Lead sponsor
- CinDome Pharma, Inc.Industry
- Sponsor type
- Industry
- First posted
- Jul 19, 2019
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Sequential
- Masking
- Triple (participant, care provider, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 70 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a randomized, double-blind, placebo-controlled Phase 2A study to evaluate safety, efficacy, PK, and dose response of oral CIN-102 in adults with idiopathic and diabetic gastroparesis. The study will assess three oral doses of CIN-102 versus placebo in three separate cohorts.
Conditions
- Gastroparesis
Interventions
CIN-102 Dose 1Drug
CIN-102 Dose 1
CIN-102 Dose 2Drug
CIN-102 Dose 2
CIN-102 Dose 3Drug
CIN-102 Dose 3
PlaceboDrug
Placebo
Primary outcomes
What the sponsor says the trial is designed to measure.
- The Change From Baseline in Gastric Emptying (GE) as Measured by the Gastric Emptying Breath Test (GEBT) Half-Time (T1/2)Time frame: Baseline (gathered between Days -10 to -3, prior to first dose of study drug) to Day 14
- The Percent Change From Baseline in Gastric Emptying (GE) as Measured by the Gastric Emptying Breath Test (GEBT) Half-Time (T1/2)Time frame: Baseline (gathered between Days -10 to -3, prior to first dose of study drug) to Day 14
Locations
19 sites in 1 country. Site status is shown where the registry gives one.
Research Site 101
Chula Vista, California
Research Site 114
Jacksonville, Florida
Research Site 117
Miami, Florida
Research Site 118
Miami, Florida
Research Site 111
Atlanta, Georgia
Research Site 110
Kansas City, Kansas
Research Site 103
Louisville, Kentucky
Research Site 112
Marrero, Louisiana
Research Site 104
Monroe, Louisiana
Research Site 102
Boston, Massachusetts
Research Site 121
Omaha, Nebraska
Research Site 113
Las Vegas, Nevada
Research Site 109
Great Neck, New York
Research Site 120
Winston-Salem, North Carolina
Research Site 105
Tulsa, Oklahoma
Research Site 106
Philadelphia, Pennsylvania
Research Site 119
Summerville, South Carolina
Research Site 115
Rapid City, South Dakota
Research Site 107
Jackson, Tennessee
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.